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While several transcription factors are known to increase insulin production and secretion, their
therapeutic potential for treatment of type 2 diabetes remains unrealized. In this issue, Goulley
et al. (2007) show that BMP signaling specifically regulates genes involved in insulin production
and secretion and demonstrate that exogenous BMP4 administration augments glucose-stimulated
insulin secretion in vivo.Type 2 diabetes results from com-
bined insulin resistance in peripheral
insulin-responsive tissues (liver, mus-
cle, and fat) and decreased functional
b cell mass. In normal b cells, glucose
metabolism leads to increased intra-
cellular ATP, closure of ATP-depen-
dent K+ channels, membrane depolar-
ization, and Ca2+ influx, resulting in
insulin granule exocytosis (Figure 1A).
The b cells of individuals with type 2
diabetes exhibit decreased glucose-
stimulated insulin secretion (GSIS).
Several transcription factors are
known to regulate insulin gene expres-
sion and mature b cell function (Jen-
sen, 2004). However, much less is
known about the secreted signals
regulating GSIS. Therapeutically, ad-
ministration of a circulating factor to
enhance insulin secretion is much
more tangible than trying to increase
expression or activity of a b cell tran-
scription factor. Insulin itself acts in
an autocrine manner to stimulate fur-
ther insulin production and secretion
(Otani et al., 2004). In addition, the
incretin hormones glucagon-like poly-
peptide-1 (GLP-1) and glucose-de-
pendent insulinotropic polypeptide
(GIP) act in a paracrine manner to en-
hance GSIS following a meal. GLP-1
also has long-term effects on the b
cell, including increased insulin gene
transcription through activation of the
IPF1/PDX1 transcription factor, in-
creased b cell proliferation, and in-
creased b cell survival (Nielsen et al.,
2001). Indeed, GLP-1 analogs are cur-
rently in use in the treatment of type 2
diabetes. In this issue of Cell Metabo-lism, Goulley et al. (2007) provide
strong evidence that bone morphoge-
netic proteins (BMPs) should be added
to the list of secreted factors that stim-
ulate insulin production and secretion.
Members of the transforming
growth factor b (TGF-b) superfamily
of growth factors include TGF-b itself,
activins, and BMP. TGF-b, activin,
and their receptors have been shown,
through gene inactivation and trans-
genic overexpression studies, to play
a role in islet morphogenesis and es-
tablishment of b cell mass (Kim et al.,
2000; Sanvito et al., 1994; Smart
et al., 2006; Yamaoka et al., 1998). In
general, inhibition of TGF-b signaling
results in decreased islet mass, in-
creased numbers of a cells, and poorly
organized islets, while enhanced
TGF-b signaling results in increased
endocrine mass at the expense of the
exocrine pancreas. In adult islets,
TGF-b has been shown to enhance in-
sulin production and secretion. Loss of
activin receptor signaling causes a se-
vere reduction in insulin and glucagon
expression and a marked reduction
in the size and number of islets. To
date, BMP signaling has been impli-
cated only in very early aspects of pan-
creas specification in zebrafish and
chick and in induction of insulin gene
expression in cell lines (Song et al.,
2006; Yew et al., 2005). Prior to the
present study by Goulley et al. (2007),
it was unknown whether BMP signal-
ing plays a role in b cell mass regula-
tion or mature b cell function.
Goulley et al. (2007) found that
BMPR1A (also known as ALK3) andCell Metabolismits high-affinity ligand BMP4 were
expressed throughout the pancreatic
epithelium at embryonic day (E) 13
but were restricted to endocrine clus-
ters in E15 embryos or islets in neo-
nates. Expression was also detected
by RT-PCR in adult islets from mice
and humans. BMP4 was the only
BMPR1A ligand expressed in islet en-
docrine cells beginning at the second-
ary transition (E13.5–E18.5), the period
during which the majority of cells that
will give rise to mature adult islets
are generated. No colabeling studies
were performed, so it is unclear
whether BMP4 and its receptor are ex-
pressed only in b cells; however, these
expression analyses suggest that an
autocrine BMP signaling pathway is
operative in at least the b cell popula-
tion (Figure 1B). The authors then ex-
amined the role of BMP signaling in
pancreas development and mature
b cell function by generating and char-
acterizing multiple complementary
transgenic and knockout mouse lines
in which BMP signaling was either
inhibited or augmented in the mouse
pancreas. Since null mutations in
Bmpr1a result in early embryonic le-
thality (Mishina et al., 1995), the au-
thors used a floxed allele of Bmpr1a
(Ming Kwan et al., 2004) to inactivate
the gene specifically in b cells using
the rat insulin promoter to drive
expression of Cre recombinase (Ins-
Cre). Alternative strategies to interfere
with BMP signaling included the use
of the Ipf1/Pdx1 promoter to express
cDNAs for a dominant-negative
(dn) Bmpr1a, the extracellular BMP5, March 2007 ª2007 Elsevier Inc. 157
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PreviewsFigure 1. BMP Signaling Affects Insulin Production and Secretion in Pancreatic b Cells
(A) Glucose is taken up by the b cell through themembrane-bound GLUT2 transporter. In the cytoplasm, glucose is phosphorylated by glucokinase to
initiate glycolysis. ATP produced during glucose metabolism binds to and inactivates the plasma membrane potassium channel, thus allowing an
inward flow of Ca2+ ions. This influx of Ca2+ causes the insulin-containing vesicles to fuse with the plasmamembrane, releasing insulin into the blood-
stream.
(B) b cells produce and secrete BMP4, which binds to a heteromeric type 1 and type 2 receptor, resulting in phosphorylation of the type 1 receptor and
its downstream second messenger, Smad1/5/8. Phosphorylated Smad1 dimerizes with the ubiquitous Smad4 and translocates to the nucleus to
mediate transcription of downstream target genes. In the b cell, these include genes involved in insulin transcription and processing (shown in the
nucleus) as well as Bmpr1a itself and genes important for glucose sensing, secretion coupling, granule fusion, and insulin secretion (underlined).inhibitor noggin, and the intracellular
inhibitor of BMP signaling Smad6
throughout the developing pancreas.
Animals lacking BMPR1A in b cells
were healthy and indistinguishable
from control littermates until 2–3
months of age, at which time they
showed an impaired ability to clear
a glucose load from the bloodstream
during an intraperitoneal glucose toler-
ance test. These mice eventually pro-
gressed to overt diabetes by about
6months of age. Total endocrine mass
and a:b cell ratio were unchanged in
Bmpr1a mutants, and thus, the au-
thors conclude that BMP signaling in
the pancreas is not required for islet/
b cell development. This group has
previously shown that this Ins-Cre
line of mice exhibits significant recom-
bination in b cells only after weaning
(3–5 weeks after birth) (Ahlgren et al.,
1998). It is unclear in the present study
whether the Bmpr1a gene is com-
pletely inactivated embryonically or
only in adult islets; thus, taken alone,
these data would be insufficient proof
for a lack of requirement of BMP4/
BMPR1A signaling in islet b cell devel-
opment or a specific role in mainte-
nance of postnatal b cell function.
However, the elegance of the study
lies in the multiple approaches used
to interfere with BMP4/BMPR1A sig-158 Cell Metabolism 5, March 2007 ª200naling. Overexpression of dnBmpr1a,
noggin, or Smad6 in the pancreas
results in the same phenotype as
b cell-specific Bmpr1a inactivation.
The diabetes associated with loss of
BMP signaling was characterized by
a dramatic decrease in GSIS as well
as loss of responsiveness to other
nonglucose secretagogues. There-
fore, unlike TGF-b or activin signaling,
BMP4/BMPR1A signaling is not re-
quired for establishing b cell mass or
isletmorphogenesis but instead seems
to be required only for maintenance of
mature b cell function.
Quantitative RT-PCR revealed that
reduced BMP signaling decreased ex-
pression of Bmpr1a itself, suggesting
a positive feedback loop similar to
that described for signaling by insulin
through its receptor in the b cell. In ad-
dition, expression of genes important
for several aspects of GSIS was sig-
nificantly reduced in the absence of
BMPR1A signaling, including genes in-
volved in glucose sensing and glucose
metabolism (Glut2 and glucokinase
[GCK]), secretion coupling (Kir6.2 and
SUR1), insulin expression and pro-
cessing (Ipf1/Pdx1, insulin [Ins], PC1/
3, andPC2), and insulin granule exocy-
tosis (Rab3d, Rab27a, calpain-10, and
SNAP-25). Interestingly, several of
these BMP targets (Ipf1/Pdx1, GCK,7 Elsevier Inc.and calpain-10) are known susceptibil-
ity genes for type 2 diabetes.
In case the multiple experiments to
inactivate BMPR1A signaling were not
convincing enough, the authors also
performed the converse experiment
by overexpressing Bmp4 under the
control of the Ipf1/Pdx1 promoter and
again found no alterations in pancreas
development or b cell mass, but rather
a specific enhancement of postnatal
b cell function and improved GSIS.
Genes found to be downregulated in
theabsenceofBMPR1Asignalingwere
upregulated in the face of increased
BMP4, strongly suggesting that these
genes are coordinately regulated in
response to autocrine BMP signaling
in the b cell (Figure 1B). The authors
pave the way for future therapeutic
potential of BMP to augment GSIS by
showing that injection of recombinant
BMP4 stimulates insulin secretion and
improves glucose tolerance in wild-
type mice without causing hypogly-
cemia—i.e., the effects of BMP4 are
glucose dependent—and, further-
more, that BMP4 can ameliorate the
impaired glucose tolerance present in
Ipf1/Pdx1 heterozygous mutant mice.
The identification of extracellular
signals that stimulate GSIS provides
great therapeutic potential for patients
with type 2 diabetes. The specificity of
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PreviewsBMP4 in this process awaits the b cell-
specific inactivation of theBmp4 gene,
a floxed allele of which already exists.
However, as mentioned above, both
Bmp4 and Bmpr1a are expressed in
adult human islets, suggesting that
this pathway is operational in humans
and thusmay be a target for enhancing
insulin secretion in man.
REFERENCES
Ahlgren, U., Jonsson, J., Jonsson, L., Simu, K.,
and Edlund, H. (1998). Genes Dev. 12, 1763–
1768.
Goulley, J., Dahl, U., Baeza, N., Mishina, Y.,
and Edlund, H. (2007). Cell Metab. 5, this issue,
207–219.Sweet Dreams fo
Mitchell A. Lazar1,* and Timothy M. W
1Division of Endocrinology, Diabetes, and
Metabolism, University of Pennsylvania Sc
2Discovery Medicinal Chemistry, Molecula
*Correspondence: lazar@mail.med.upenn.
DOI 10.1016/j.cmet.2007.02.001
Nuclear receptors (NRs) are tran
small lipophilic ligands. The liver X
ulate lipid metabolism upon bindi
LXR activity is also regulated by
LXR inmetabolic sensing and gen
affinity for LXR present a challen
Nuclear receptors (NR) are an impor-
tant family of transcription factors
that play a major role in the regulation
of cellular metabolism (Chawla et al.,
2001). First characterized about 20
years ago, the founding members of
the NR family are receptors for steroid
and thyroid hormones that are proven
targets for important pharmaceutical
drugs. The human genome contains
a total of 48 NRs, the majority of which
do not bind to these classical endo-
crine hormones. Over the past two
decades, natural as well as synthetic
ligands have been identified for addi-
tional NRs, including related receptors
for biologically active metabolites of
the fat-soluble vitamins A and D. A re-
markable range of naturally occurringJensen, J. (2004). Dev. Dyn. 229, 176–200.
Kim, S.K., Hebrok, M., Li, E., Oh, S.P.,
Schrewe, H., Harmon, E.B., Lee, J.S., andMel-
ton, D.A. (2000). Genes Dev. 14, 1866–1871.
Ming Kwan, K., Li, A.G., Wang, X.J., Wurst, W.,
and Behringer, R.R. (2004). Genesis 39, 10–25.
Mishina, Y., Suzuki, A., Ueno, N., and
Behringer, R.R. (1995). Genes Dev. 9, 3027–
3037.
Nielsen, J.H., Galsgaard, E.D., Moldrup, A.,
Friedrichsen, B.N., Billestrup, N., Hansen,
J.A., Lee, Y.C., and Carlsson, C. (2001). Diabe-
tes 50, S25–S29.
Otani, K., Kulkarni, R.N., Baldwin, A.C., Krutz-
feldt, J., Ueki, K., Stoffel, M., Kahn, C.R., and
Polonsky, K.S. (2004). Am. J. Physiol. Endocri-
nol. Metab. 286, E41–E49.r LXR
illson2,*
Metabolism, Department of Medicine, The In
hool of Medicine, Philadelphia, PA 19104, U
r Discovery Research, GlaxoSmithKline, Res
edu (M.A.L.), tim.m.willson@gsk.com (T.M.W
scription factors whose activities
receptors (LXRs) are an important
ng to cholesterol metabolites calle
binding to glucose (Mitro et al., 20
e regulation. However, the hydrop
ge to central dogma about the nat
molecules have been shown to bind
and regulate ‘‘orphan’’ NRs (Table 1).
These discoveries have provoked de-
bate as to the criteria a molecule
should fulfill to be anointed as a physi-
ological ligand. A case in point is the
liver X receptor (LXR), an important
regulator of lipid metabolism whose
activity is controlled by cholesterol
metabolites called oxysterols (see
Zelcer and Tontonoz, 2006 for a gen-
eral review). A recent report fromMitro
et al. (2007) has complicated this sim-
ple picture by suggesting that LXR
may function as a sensor for glucose
in addition to sterol metabolites.
There are two LXR subtypes, one
that is predominantly expressed in
the liver (LXRa, also called RLD-1;
Cell MetabolismSanvito, F., Herrera, P.L., Huarte, J., Nichols,
A., Montesano, R., Orci, L., and Vassali, J.D.
(1994). Development 120, 3451–3462.
Smart, N.G., Apelqvist, A.A., Gu, X., Harmon,
E.B., Topper, J.N., MacDonald, R.J., and
Kim, S.K. (2006). PLoS Biol. 4, e39.
Song, J., Kim, H.J., Gong, Z., Liu, N.A., and Lin,
S. (2006). Dev. Biol., in press. Published online
December 1, 2006. 10.1016/j.ydbio.2006.11.
040.
Yamaoka, T., Idehara, C., Yano, M., Matsush-
ita, T., Yamada, T., Ii, S., Moritani, M., Hata,
J., Sugino, H., Noji, S., and Itakura, M. (1998).
J. Clin. Invest. 102, 294–301.
Yew, K.H., Hembree, M., Prasadan, K., Pre-
uett, B., McFall, C., Benjes, C., Crowley, A.,
Sharp, S., Tulachan, S., Mehta, S., et al.
(2005). J. Biol. Chem. 280, 32209–32217.stitute for Diabetes, Obesity, and
SA
earch Triangle Park, NC 27709, USA
.)
are modulated by the binding of
pair ofmammalian NRs that reg-
d oxysterols. A recent report that
07) expands the potential role of
hilic nature of glucose and its low
ure of the NR-ligand interaction.
NR1H3) and one that is widely
expressed (LXRb, also called UR;
NR1H2). LXRa was first described as
an orphan receptor; soon thereafter,
its activity was shown to be regulated
by retinoids, which bind to its hetero-
dimer partner RXR (Willy et al., 1995).
Subsequently, oxysterols were found
to activate LXR (Janowski et al.,
1996), and biochemical and crystallo-
graphic studies prove that they do so
by binding directly to the typical hy-
drophobic pocket in the C-terminal
domain (Williams et al., 2003). The role
of oxysterols as physiological ligands
fits with their lipophilic nature, as well
as with the phenotype of mice lacking
LXRa, whose livers become filled with
cholesterol when fed a Western diet
5, March 2007 ª2007 Elsevier Inc. 159
